Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2002. Start Trial.
Date Value
June 30, 2026 60.45%
March 31, 2026 44.87%
December 31, 2025 37.04%
September 30, 2025 48.58%
June 30, 2025 55.37%
March 31, 2025 50.69%
December 31, 2024 59.96%
September 30, 2024 42.79%
June 30, 2024 50.38%
March 31, 2024 31.90%
December 31, 2023 66.00%
September 30, 2023 62.43%
June 30, 2023 65.58%
March 31, 2023 65.78%
December 31, 2022 73.48%
September 30, 2022 61.76%
June 30, 2022 19.64%
March 31, 2022 8.71%
December 31, 2021 27.24%
September 30, 2021 30.85%
June 30, 2021 32.62%
March 31, 2021 29.47%
December 31, 2020 -42.82%
September 30, 2020 55.12%
June 30, 2020 45.75%
Date Value
March 31, 2020 33.48%
December 31, 2019 55.27%
September 30, 2019 36.59%
June 30, 2019 50.86%
March 31, 2019 38.85%
December 31, 2018 39.38%
September 30, 2018 63.70%
June 30, 2018 47.12%
March 31, 2018 -69.17%
December 31, 2017 57.38%
September 30, 2017 83.35%
June 30, 2017 60.92%
March 31, 2017 67.03%
December 31, 2016 67.27%
September 30, 2016 59.49%
June 30, 2016 75.70%
March 31, 2016 15.51%
December 31, 2015 46.63%
September 30, 2015 44.73%
June 30, 2015 71.73%
March 31, 2015 59.71%
December 31, 2014 65.43%
September 30, 2014 52.53%
June 30, 2014 44.98%
March 31, 2014 45.40%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
Evaxion AS --
Genmab A/S 92.73%
Ascendis Pharma A/S 90.64%
Zealand Pharma A/S 99.76%
Agenus, Inc. 98.50%

Gross Profit Margin (Quarterly) Related Metrics